GMX Reliance Gen.

RNS Number:6086X
GeneMedix PLC
01 June 2007



FOR IMMEDIATE RELEASE                                              1st June 2007


                                 GeneMedix plc
                                 Trading update


GeneMedix plc ("GeneMedix" or "the Company"), the AIM listed biopharmaceutical
company, today releases a trading update ahead of its results for the 16 months
ended 31st March 2007.


The Board is pleased to announce that, since the completion of its strategic
alliance and financing with Reliance Life Sciences Pvt Ltd's ("RLS") and the
Company's admission to trading on AIM on 16th February 2007, the Company has
continued to make good progress in the clinical development of its lead compound
EPO. Expenditure to date has been in line with management's expectations. As a
result of the financing with RLS and the conversion of certain convertible loan
notes, the Company's balance sheet has been considerably strengthened. At 31st
March 2007 the Company had net cash of #9.3 million.


Following the extension to its accounting period, GeneMedix wishes to indicate
the reporting dates for its results. The audited accounts for the 16 months
ended 31st March 2007 will be published by 31st July 2007. The unaudited interim
accounts for the 6 months ending 30th September 2007 will be published by 31st
December 2007.


ENQUIRIES:

GeneMedix plc                                                 Tel: 01638 663320
Julian Attfield, Chief Executive Officer


Bankside Consultants                                         Tel: 020 7367 8888
Michael Padley/ Susan Scott



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
TSTGGGGVGMNGNZM

Reliance Genemedix (LSE:GMX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Reliance Genemedix (LSE:GMX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024